Search

Your search keyword '"Yong, Michelle C.R."' showing total 27 results
Start Over Author "Yong, Michelle C.R."
27 results on '"Yong, Michelle C.R."'

1. Data from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Author

Blake, Stephen J., primary, Stannard, Kimberley, primary, Liu, Jing, primary, Allen, Stacey, primary, Yong, Michelle C.R., primary, Mittal, Deepak, primary, Aguilera, Amelia Roman, primary, Miles, John J., primary, Lutzky, Viviana P., primary, de Andrade, Lucas Ferrari, primary, Martinet, Ludovic, primary, Colonna, Marco, primary, Takeda, Kazuyoshi, primary, Kühnel, Florian, primary, Gurlevik, Engin, primary, Bernhardt, Günter, primary, Teng, Michele W.L., primary, and Smyth, Mark J., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure S1 from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Author

Blake, Stephen J., primary, Stannard, Kimberley, primary, Liu, Jing, primary, Allen, Stacey, primary, Yong, Michelle C.R., primary, Mittal, Deepak, primary, Aguilera, Amelia Roman, primary, Miles, John J., primary, Lutzky, Viviana P., primary, de Andrade, Lucas Ferrari, primary, Martinet, Ludovic, primary, Colonna, Marco, primary, Takeda, Kazuyoshi, primary, Kühnel, Florian, primary, Gurlevik, Engin, primary, Bernhardt, Günter, primary, Teng, Michele W.L., primary, and Smyth, Mark J., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Methods, Figure Legends, Table S1 from Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

Author

Liu, Jing, primary, Blake, Stephen J., primary, Yong, Michelle C.R., primary, Harjunpää, Heidi, primary, Ngiow, Shin Foong, primary, Takeda, Kazuyoshi, primary, Young, Arabella, primary, O'Donnell, Jake S., primary, Allen, Stacey, primary, Smyth, Mark J., primary, and Teng, Michele W.L., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Methods, Figure Legends from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Author

Blake, Stephen J., primary, Stannard, Kimberley, primary, Liu, Jing, primary, Allen, Stacey, primary, Yong, Michelle C.R., primary, Mittal, Deepak, primary, Aguilera, Amelia Roman, primary, Miles, John J., primary, Lutzky, Viviana P., primary, de Andrade, Lucas Ferrari, primary, Martinet, Ludovic, primary, Colonna, Marco, primary, Takeda, Kazuyoshi, primary, Kühnel, Florian, primary, Gurlevik, Engin, primary, Bernhardt, Günter, primary, Teng, Michele W.L., primary, and Smyth, Mark J., primary

Published
2023
Full Text
View/download PDF

22. Immunosurveillance and therapy of multiple myeloma are Cd226 dependent

Author

Guillerey, Camille, de Andrade, Lucas Ferrari, Vuckovic, Slavica, Miles, Kim, Ngiow, Shin Foong, Yong, Michelle C.R., Teng, Michele W.L., Colonna, Marco, Ritchie, David S., Chesi, Martha, Bergsage, P. Leif, Hill, Geoffrey R., Smyth, Mark J., and Martinet, Ludovic

Subjects
T cells -- Physiological aspects -- Research, Immunotherapy -- Health aspects -- Research, Multiple myeloma -- Care and treatment -- Research, Health care industry
Abstract

Multiple myeloma (MM) is an age-dependent hematological malignancy. Evaluation of immune interactions that drive MM relies on in vitro experiments that do not reflect the complex cellular stroma involved in MM pathogenesis. Here we used Vk*MYC transgenic mice, which spontaneously develop MM, and demonstrated that the immune system plays a critical role in the control of MM progression and the response to treatment. We monitored Vk*MYC mice that had been crossed with Cd226 mutant mice over a period of 3 years and found that CD226 limits spontaneous MM development. The CD226dependent anti-myeloma immune response against transplanted Vk*MYC MM cells was mediated both by NK and [CD8.sup.+] T cells through perforin and IFN-γ pathways. Moreover, CD226 expression was required for optimal antimyeloma efficacy of cyclophosphamide (CTX) and bortezomib (Btz), which are both standardly used to manage MM in patients. Activation of costimulatory receptor CD137 with mAb (4-1BB) exerted strong antimyeloma activity, while inhibition of coinhibitory receptors PD-1 and CTLA-4 had no effect. Taken together, the results of this study provide in vivo evidence that CD226 is important for MM immunosurveillance and indicate that specific immune components should be targeted for optimal MM treatment efficacy. As progressive immunosuppression associates with MM development, strategies aimed to increase immune functions may have important therapeutic implications in MM., Introduction Multiple myeloma (MM) is the second most common hematological malignancy in the world (1). Despite recent progress in new therapeutic options, this disease remains incurable, with a median survival [...]

Published
2015
Full Text
View/download PDF

25. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Author

Blake, Stephen J., primary, Stannard, Kimberley, additional, Liu, Jing, additional, Allen, Stacey, additional, Yong, Michelle C.R., additional, Mittal, Deepak, additional, Aguilera, Amelia Roman, additional, Miles, John J., additional, Lutzky, Viviana P., additional, de Andrade, Lucas Ferrari, additional, Martinet, Ludovic, additional, Colonna, Marco, additional, Takeda, Kazuyoshi, additional, Kühnel, Florian, additional, Gurlevik, Engin, additional, Bernhardt, Günter, additional, Teng, Michele W.L., additional, and Smyth, Mark J., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results